http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2579039-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50eb752940fa4aa36756a6bc9f6f3504 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5044 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6872 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-567 |
| filingDate | 2012-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_973ff7ce33b9c5f730a90445e1a94cfb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f401c2d33dd24d7b79e9cff2600bc02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b0e65f6722dab22c8233aa56f25f2bc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1a6b469702ae645722da071e1ed698f |
| publicationDate | 2013-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2579039-A1 |
| titleOfInvention | Neuropeptide release assay for sodium channels |
| abstract | Methods and compositions for using genetically modified non-human animals are provided, wherein the genetic modification comprises a humanization of the one or more extracellular pore loops of a Na v 1.7 channel protein or a complete humanization of an endogenous Na v 1.7 gene, in particular a method of measuring nonciceptive function of dorsal root ganglia (DRG). Methods for using isolated DRG cultures from genetically modified non-human animals are also provided, wherein the isolated DRG express a human or chimeric Na v 1.7 protein on the surface, in particular measuring primary nociceptor activation through the release of calcitonin gene-related peptide (CGRP) in isolated DRG in vitro, and wherein the isolated DRG cultures are capable of generating action potentials and communicating through an excitable signal via the expressed human or chimeric Na v 1.7 protein the cell surface. In vivo and in vitro methods for characterizing Na V 1.7-specific antagonists and evaluation of corresponding therapeutic potential for Na V 1.7-mediated disease are also provided. |
| priorityDate | 2011-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 260.